On January 8, 2025, the Hurun Global Gazelles Conference 2025 was held in Beijing Economic and Technological Development Area. At this conference, the much-anticipated Hurun Global Gazelles Index 2024 was grandly released. This list showcases high-growth enterprises globally that were founded after 2000 and are most likely to reach the unicorn valuation of one billion US dollars within three years. As an innovative leader in the ophthalmology field driven by a dual-engine model, Arctic Vision has won the "Hurun Global Gazelles 2024" award, thanks to its differentiated corporate positioning and innovative ophthalmic product pipeline.

During the conference, experts and scholars from fields across high technology, healthcare, and finance gathered to deeply analyze industry trends and discuss how new technologies can boost the development of the new economy. Mr. York Chen, the co-founder and Chief Commercial Officer of Arctic Vision, was invited to attend the award ceremony and presented a speech at the Biotechnology and Big Health Forum.

During his speech, Mr. Chen shared the core development strategy of Arctic Vision's innovative ophthalmic therapies – the "Dual-Engine" strategy guided by "cutting-edge technologies" and "consumer-oriented technologies". These two engines define the boundaries for the development of the company’s pipeline. The selection and development of all products can find their positions on the spectrum with cutting-edge technologies and consumer-oriented technologies at the two ends. This not only addresses the unmet needs in the field of ophthalmic treatment but also further improves the public's eye health.

About Arctic Vision

Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products. For more information, please visit https://www.arcticvision.com

Investor and Media Contact

 Communications@arcticvision.com